ArticleInvestigational new drugs2018

Phase 1 and pharmacokinetic study of LY3007113, a p38 MAPK inhibitor, in patients with advanced cancer.

Jonathan W Goldman et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.